Key Takeaways Quest Diagnostics will co-develop a blood test with MD Anderson to detect elevated cancer risk. DGX will refine and validate MD Anderson's MCaST model for its lab-developed cancer risk test. DGX shares rose 2.6% after the news, adding to a 31.3% gain over the past year.Quest Diagnostics Inc. (DGX) recently announced a collaboration with The University of Texas MD Anderson Cancer Center (MD Anderson). The partnership will focus on improving the assessment of elevated risk of cancer in individ ...

Core Insights - Precipio, Inc. reported strong financial performance in Q1-2025, with a 43% year-over-year revenue increase, reaching $4.9 million [9][10] - The company anticipates continued revenue growth and a return to positive operating cash flow by Q2 or Q3 of 2025, driven by momentum in its Product business and expanded reimbursement opportunities in Pathology Services [2][8] Financial Performance - Q1-2025 revenues increased by 43% year-over-year, but decreased by 9.5% from Q4-2024 due to seasonal factors and onboarding delays [9] - Adjusted EBITDA improved significantly to ($108K) from ($1,409K) year-over-year, marking a 92% improvement [9] - Cash used in operations decreased to ($44K) in Q1-2025 from ($667K) in Q1-2024, an improvement of 93% [9] Product Division Highlights - The Products Division onboarded one new customer and launched two new panels in Q1-2025, with expectations for increased orders in Q2 [5] - Gross margins for the Products Division increased from 37% to 51% year-over-year [10] Pathology Services Division Highlights - Pathology Services revenues grew 54% year-over-year, with test volume increasing by 46% [7] - The division received MolDx approval for NGS testing, allowing Medicare billing, which is expected to positively impact future revenues [7] Operational Efficiency - Operating expenses as a percentage of net revenue decreased from 87% to 61% year-over-year, with management maintaining flat operating expenses at approximately $3 million per quarter [9] - Overall gross margins improved from 27% to 43% year-over-year, with expectations for continued growth as the revenue mix shifts towards more product sales [10]

Veracyte (VCYT) Q1 2025 Earnings Call May 07, 2025 04:30 PM ET Speaker0 and thank you for standing by. Welcome to the Veracyte First Quarter twenty twenty five Financial Results Webcast. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Sheila Gorman, Senior Director, Investor Relations. P ...